MedWatch

ALK's house dust mite tablet approved in Canada

The Danish allergy group ALK-Abello has gotten the Canadian authorities’ permission to market the company’s most promising medicine, the house dust mite (HDM) allergy tablet Acarizax.

The allergy drug group ALK now has the chance to expand its commercial operations on the Canadian market, as the country's healthcare authorities have approved ALK’s tablet Acarizax against house dust mite allergy.

“This new approval expands ALK’s tablet range in Canada, which now covers grass, ragweed and, the most common of all respiratory allergies, house dust mite. We continue to develop our organization and launch readiness in North America ahead of the introduction of this allergy tablet,” says Henrik Jacobi, ALK’s Executive Vice President, Research and Development, in a stock exchange announcement.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier